"I don't see this bio-defense sector going anywhere but up, " says Thomas Monath , chief scientific officer for Acambis (nasdaq: ACAM - news - people ).
Without a dose of biotech, DuPont's new glucose-based Bio-PDO, a chemical intermediary that scientists had dreamed of for 40 years, still wouldn't be ready.